WallStSmart

ResMed Inc (RMD)vsTurtle Beach Corporation (TBCH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 1587% more annual revenue ($5.40B vs $319.91M). RMD leads profitability with a 27.5% profit margin vs 4.9%. TBCH appears more attractively valued with a PEG of 0.80. RMD earns a higher WallStSmart Score of 70/100 (B).

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34

TBCH

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 7.3Quality: 6.0
Piotroski: 2/9Altman Z: 1.40
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued
TBCHSignificantly Overvalued (-121.8%)

Margin of Safety

-121.8%

Fair Value

$5.24

Current Price

$11.76

$6.52 premium

UndervaluedFair: $5.24Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

TBCH3 strengths · Avg: 8.0/10
PEG RatioValuation
0.808/10

Growing faster than its price suggests

P/E RatioValuation
15.3x8/10

Attractively priced relative to earnings

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

TBCH4 concerns · Avg: 2.8/10
Market CapQuality
$231.28M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
4.9%3/10

4.9% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Revenue GrowthGrowth
-18.7%2/10

Revenue declined 18.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bull Case : TBCH

The strongest argument for TBCH centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.80 suggests the stock is reasonably priced for its growth.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : TBCH

The primary concerns for TBCH are Market Cap, Profit Margin, Piotroski F-Score. Thin 4.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

RMD profiles as a mature stock while TBCH is a value play — different risk/reward profiles.

TBCH carries more volatility with a beta of 2.27 — expect wider price swings.

RMD is growing revenue faster at 11.0% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 55/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Turtle Beach Corporation

TECHNOLOGY · CONSUMER ELECTRONICS · USA

Turtle Beach Corporation is an audio technology company in North America, Europe, the Middle East, and the Asia Pacific. The company is headquartered in White Plains, New York.

Visit Website →

Want to dig deeper into these stocks?